Research | Alzheimer's Society

What is donanemab?

Donanemab, also known as Kisunla, has recently been licensed as a treatment for early-stage Alzheimer’s disease in the UK. However, donanemab has not been recommended for use in the NHS. Here's what we know about this new Alzheimer's drug.

Research

Decreased deep sleep linked to early signs of Alzheimer's disease

Study suggests that people who have fewer hours of deep sleep are more likely to show early signs of Alzheimer's disease.

Yale researchers say new compound shows promise in dementia treatment - Alzheimer's Society comment

According to a new study, Yale University researchers have identified a drinkable cocktail of molecules that interferes with a first step of Alzheimer’s disease.

Research

Is Alzheimer's disease contagious? The science still says no

17 December 2018

Dementia risk in female military veterans - Alzheimer's Society comment

A new study finds female military veterans who have traumatic brain injury, post-traumatic stress disorder (PTSD) or depression may be more likely to develop dementia.

Regular problem-solving does not protect against mental decline - Alzheimer's Society comment

Read our comment regarding the recent news that problem-solving games may not protect against a decline in mental capacity.

Real stories

A voice in research: Alzheimer’s Society turns 40

30 November 2018

£16 million European collaboration paves the way for new research – Alzheimer’s Society comment

UK Funders, including Alzheimer’s Society, have united with 15 countries across Europe, Australia and Canada to support international research collaborations into diseases of the brain, including those that cause dementia.

Study finds bias in widely used dementia tests - Alzheimer's Society comment

A study published today in Neurology Clinical Practice found that brief cognitive tests, used in primary care settings to evaluate memory and thinking in order to identify whether people are likely to have dementia, may often be wrong.

Joint Programme - Neurodegenerative Diseases

Alzheimer’s Society, along with other UK funders, has committed £2.15million to the Joint Programme - Neurodegenerative Diseases (JPND). Find out about the UK highlights from the programme here.

Global organisations unite to change brain health and dementia landscape

Three leading organisations have joined forces to address the growing public health crisis of Alzheimer’s disease.

Gap In Life Expectancy Between Richest And Poorest Widens, Study Finds

A "perfect storm" of stagnating wages and benefits cuts has led to the gap in life expectancy between the richest and poorest in the England widening, according to new research.

DNA vaccine reduces toxic proteins linked to Alzheimer's disease - Alzheimer's Society comment

A study has found that a DNA vaccine tested in mice reduces accumulation of both toxic proteins associated with Alzheimer's disease (beta-amyloid and tau).